PRNAF — ALTERITY THERAPEUTICS LTD
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1131343 ·
Australia
Last close
$0.40
Market Cap
$87.40M
52W High
$0.55
52W Low
$0.00
ADV30
83
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | — | — | — | — | 46,019,461 | 37,317,962 | 3,294,499 |
| Dec 2025 | — | — | — | — | 56,918,905 | 49,200,547 | 2,650,906 |
| Jun 2025 | — | — | — | — | 46,026,360 | 33,158,642 | 3,623,274 |
| Dec 2024 | — | — | — | — | 10,546,933 | 4,536,559 | 2,760,926 |
Balance + Analyst (yfinance extras)
Retained Earnings
$-234,379,461
Inventory
—
Receivables
$6,842,493
ST Investments
$7,500,000
EBIT TTM
—
Pretax Income TTM
—
Interest Exp TTM
—
Analysts
—
Yahoo Snapshot (yfinance, live)
Total Revenue
$3,610,016
EBITDA
$-25,090,684
Free Cash Flow
$-14,740,514
Enterprise Value
$50,275,672
Total Cash
$37,317,960
Total Debt
$193,465
Shares Out
218,500,420
Trailing EPS
$-0.08
Book Value
$0.14
ROE
-55.0%
ROA
-34.1%
Div Yield
—
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | -25,094,229 | -23,400,949 | 46,019,461 | 3,294,499 | 42,724,962 | — |
| Jun 2025 | 0 | -12,461,203 | -12,147,828 | 46,026,360 | 3,623,274 | 42,403,086 | -11,451,248 |
| Jun 2024 | 0 | -19,616,621 | -19,123,464 | 19,223,743 | 5,425,686 | 13,798,057 | -12,605,824 |
| Jun 2023 | 0 | -14,653,292 | -13,806,515 | 27,317,636 | 4,504,727 | 22,812,909 | -20,035,837 |
| Jun 2022 | — | — | — | — | — | — | -12,337,274 |
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| RVRC | Revium Rx. | $86.84M | $1.43 | — |
| ACRV | Acrivon Therapeutics, Inc. | $88.28M | $2.06 | — |
| RANI | Rani Therapeutics Holdings, Inc. | $89.57M | $0.78 | — |
| ONCY | ONCOLYTICS BIOTECH INC | $84.54M | $0.66 | — |
| RLYB | Rallybio Corp | $90.54M | $17.05 | — |
News headlines (Yahoo Finance, 1h cache)
Alterity Therapeutics CEO speaks with Proactive at the ASX SMIDcaps Conference
2026-09-23 09:07 · Yahoo
Alterity Therapeutics to Participate in a Fireside Chat at the Cantor Global Healthcare Conference 2026
2026-09-03 11:05 · Yahoo
Alterity Therapeutics Announces Granting of New U.S. Composition of Matter Patent for ATH434
2026-08-12 11:05 · Yahoo
Alterity Therapeutics to Present at the 46th Annual Canaccord Genuity Growth Conference
2026-08-06 11:25 · Yahoo
Alterity Therapeutics Releases Appendix 4C – Q4 FY26 Quarterly Cash Flow Report & Corporate Update
2026-07-30 11:25 · Yahoo
Alterity Therapeutics to Participate in the Virtual BTIG Biotechnology Conference 2026
2026-07-21 11:25 · Yahoo
Alterity Therapeutics Receives FDA End-of-Phase 2 Meeting Minutes Confirming Registrational Pathway for ATH434 in Multiple System Atrophy
2026-07-07 11:05 · Yahoo
Alterity Therapeutics Achieves Alignment with U.S. FDA on Pivotal Phase 3 Program for ATH434 in Multiple System Atrophy
2026-06-09 11:05 · Yahoo
Alterity Therapeutics Data Presentations Support Advancement of ATH434 into Phase 3 in Multiple System Atrophy
2026-05-19 11:25 · Yahoo
Alterity Therapeutics Announces Publication Demonstrating the Utility of Quantitative MRI as a Biomarker for Multiple System Atrophy
2026-05-11 11:25 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.